Digital change management system for respirator filter cartridges

The European Patent Office published patent EP4168082A1 granting 3M Innovative Properties Company intellectual property rights for a digital change management system for respirator filter cartridges. The patent covers methods and systems for tracking, scheduling, and managing replacement intervals of filter cartridges used in respirators and breathing apparatus.

Cohort Sleep Performance Evaluation - ResMed EP4264631A1

The EPO published ResMed Sensor Technologies Limited's patent application EP4264631A1 for a cohort sleep performance evaluation system. The invention enables comparative analysis of sleep data across groups of patients using health informatics methods. The patent covers IPC classifications G16H 50/30 and G16H 50/50 related to population-level sleep assessment.

ResMed sleep disorder identification and treatment systems

The European Patent Office published patent EP4173005A1 for ResMed Pty Ltd, covering systems and methods for identifying individuals with sleeping disorders and disposition for treatment. The patent application includes IPC classifications G16H 50/20, A61B 5/00, G16H 10/60, and G16H 50/70. The designated states cover all relevant EU member states and extension countries.

Systems and Methods for Mental Health Assessment

The European Patent Office granted patent EP4232972A1 to Tibi Health, Inc. covering machine learning systems for mental health assessment. The patent, filed by inventors Ozem Irmak and Simal Irmak, includes claims across multiple health informatics classifications (G16H) and grants Tibi Health exclusive IP rights across 32 designated European states including Germany, France, the UK, Italy, and Spain.

IL-33 antagonist therapeutic agent, Mitsubishi Tanabe Pharma, endometriosis, EP3677281A1

IL-33 antagonist therapeutic agent, Mitsubishi Tanabe Pharma, endometriosis, EP3677281A1

Axl inhibitor therapeutic agent for solid cancers

The European Patent Office has granted Patent EP3695839A1 to ONO Pharmaceutical Co., Ltd. and Kyoto Prefectural Public University Corporation, covering an Axl inhibitor therapeutic agent for treating solid cancers. The patent protects novel compound compositions and their pharmaceutical applications. Designated states include all EU member states plus Switzerland, Norway, and other EPC contracting states.

Pyrrolo and imidazo pyridine compounds, protein kinase inhibitors, therapeutic applications

EPO published patent EP3697787A1 for HK inno.N Corporation covering pyrrolo[2,3-b]pyridine and imidazo[4,5-b]pyridine compounds as protein kinase inhibitors for therapeutic applications including cancer, metabolic, and neurological disorders.

Nucleic Acids Inhibiting Tmprss6 for Therapy

The European Patent Office published Patent EP3826720A2 granting Silence Therapeutics GmbH protection for nucleic acid compositions that inhibit Tmprss6 gene expression for therapeutic applications including iron chelation and neurological disorders. The patent covers A61K formulations and C12N15/113 classified nucleic acid sequences across 27 designated contracting states.

Method for Isolating Dopamine Neurons and Pharmaceutical Composition for Parkinson's Disease

The EPO granted Patent EP3591039A1 to S-BIOMEDICS covering a method for isolating dopamine neurons and a pharmaceutical composition containing those neurons for treating Parkinson's disease. The patent, with inventors KIM Dong-Wook, YOO Jeong-Eun, LEE Dongjin, PARK Sanghyun, KIM Jongwan, and CHO Myung Soo, designates 44 European states. The invention is classified under IPC categories for cell culture (C12N 5/0793), CNS-active pharmaceutical compositions (A61K 35/30), and anti-Parkinson agents (A61P 25/16).

Immunebridge Stem Cell Expansion Patent - Fluorene Derivatives

The European Patent Office published patent EP3700334A1 granted to Immunebridge Inc. covering compositions and methods for expanding hematopoietic stem cells using fluorene derivatives. The patent names inventors Jesse Cotari, Timothy Webb, and Zhan Wang, with broad IPC classifications spanning chemical compounds (C07C, C07D), pharmaceutical preparations (A61K), and therapeutic applications (A61P). The patent is designated across 32 European member states.